AQUACEL^® Ag Advantage

1. Bowler PG, Parsons, D. Combatting wound bio¬film and recalcitrance with a novel anti-bio¬film Hydrofiber® wound dressing. Wound Medicine. 2016; 14: 6–11.
2. WHRI4796 MA271 – data on ¬file.
3. Hurlow, Bowler. Potential implications of bio¬film in chronic wounds: a case series. J Wound Care 2012; 21: 109-119.
4. Parsons D, Meredith K, Rowlands VJ, Short D, Metcalf DG, Bowler PG. Enhanced Performance and Mode of Action of a Novel Antibio¬film Hydro¬fiber® Wound Dressing. Biomed Res Int. 2016;2016:7616471.
5. Metcalf DG, Parsons D, Bowler PG. Clinical safety and effectiveness evaluation of a new antimicrobial wound dressing designed to manage exudate, infection and bio¬film. Int Wound J 2017; 14: 203-213.
6. Malone M et al. 2017. The prevalence of bio¬film in chronic wounds: a systematic review and meta-analysis of published data. JWC; 20-25.
7. National Institutes of Health, 2002. Research on microbial bio¬films. https://grants.nih.gov/grants/guide/pa- les/PA-03-047.html. Accessed October 2017.
8. Donlan RM, Costerton JW. Bio¬films: survival mechanisms of clinically relevant microorganisms. Clin Micro Rev. 2002; 15:167-193.
9. Wolcott RD et al. Bio¬film maturity studies indicate sharp debridement opens a time dependent therapeutic window. J Wound Care. 2010; 19:320-328.
10. Percival SL, Bowler PG, 2004. Bio¬films and their potential role in wound healing. WOUNDS, 16: 234-240.
11. Bowler. Antibiotic resistance and bio¬film tolerance: a combined threat in the treatment of chronic infections. JWC Vol 27;No 5; 2018.
12. Hurlow, J., Couch, K., Laforet, K., Bolton, L., Metcalf, D. et al. (2015). Clinical Biofilms: A Challenging
Frontier in Wound Care. Advances in Wound Care, 4(5), 295-301.
13. Metcalf, Bowler. Bio¬film delays wound healing: a review of the evidence. Burns Trauma 2013; 1: 5-12.
14. Gurjala AN et al. Development of a novel, highly quantitative in vivo model for the study of bio¬film-impaired cutaneous wound healing. Wound Rep Reg (2011) 19 400-410.
15. Antimicrobial activity and prevention of bio¬film reformation by AQUACEL® Ag+ Extra™ dressing. Scienti¬fic Background Report. WHRI3857 MA236, 2013, Data on ¬ le, ConvaTec Inc.
16. Antimicrobial activity against CA-MRSA and prevention of bio¬film reformation by AQUACEL® Ag+ Extra™ dressing. Scienti¬fic Background Report. WHRI3875 MA239, 2013, Data on file, ConvaTec Inc.

*AQUACEL® Ag Advantage is not a drug. All anti-microbial activity occurs within the dressing. The correlation between in-vitro testing and clinical effectiveness has not been determined.

AP-030617-MRL-US